Evidence map›Paper›PMID 37373293›Full record

ArticleInternational journal of molecular sciences2023

The Parallel Structure-Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands.

Mark D Ericson, Katie T Freeman, Travis M LaVoi, Haley M Donow, Radleigh G Santos, Marc A Giulianotti, Clemencia Pinilla, Richard A Houghten, Carrie Haskell-Luevano

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mark D EricsonDepartment of Medicinal Chemistry & Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-8715-6010
Katie T FreemanDepartment of Medicinal Chemistry & Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
Travis M LaVoiCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
Haley M DonowCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
Radleigh G SantosDepartment of Mathematics, Nova Southeastern University, Fort Lauderdale, FL 33314, USA.
Marc A GiulianottiCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
Clemencia PinillaCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
Richard A HoughtenCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
Carrie Haskell-LuevanoDepartment of Medicinal Chemistry & Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-6783-5972

Funding

Melanocortin Receptor Selective LigandsR01DK124504 · NIDDK · UNIVERSITY OF MINNESOTA · PI GIULIANOTTI, MARC, HASKELL-LUEVANO, CARRIE · 2021 to 2024
$2.8M
NIDDK NIH HHS R01 DK124504NIDDK NIH HHS R01DK124504
6 · The paper itself

Abstract

The melanocortin receptors are involved in numerous physiological pathways, including appetite, skin and hair pigmentation, and steroidogenesis. In particular, the melanocortin-3 receptor (MC3R) is involved in fat storage, food intake, and energy homeostasis. Small-molecule ligands developed for the MC3R may serve as therapeutic lead compounds for treating disease states of energy disequilibrium. Herein, three previously reported pyrrolidine bis-cyclic guanidine compounds with five sites for molecular diversity (R1-R5) were subjected to parallel structure-activity relationship studies to identify the common pharmacophore of this scaffold series required for full agonism at the MC3R. The R2, R3, and R5 positions were required for full MC3R efficacy, while truncation of either the R1 or R4 positions in all three compounds resulted in full MC3R agonists. Two additional fragments, featuring molecular weights below 300 Da, were also identified that possessed full agonist efficacy and micromolar potencies at the mMC5R. These SAR experiments may be useful in generating new small-molecule ligands and chemical probes for the melanocortin receptors to help elucidate their roles in vivo and as therapeutic lead compounds.

Indexed as

PharmacophoreReceptor, Melanocortin, Type 3GuanidineGuanidinesLigandsReceptors, MelanocortinStructure-Activity RelationshipGuanidineGuanidinesLigandsReceptor, Melanocortin, Type 3Receptors, MelanocortinmMC3R small-molecule ligandsmMC5R fragmentsparallel structure–activity relationship studies

Identifiers

PMID37373293
PMCPMC10299128

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.